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BACKGROUND: Following maximal safe resection, radiation (RT) with
concurrent and 6 cycles (C) of adjuvant temozolomide (TMZ) [Stupp NEJM
2005] has been established as standard of care for newly-diagnosed glioblasto-
ma(GBM).This regimenhasbeenadoptedwithvariations, includingextending
TMZbeyond 6 cycles. The optimal duration ofmaintenance therapy remains a
matterofdebate.OBJECTIVES:Compareoutcomesofpatientswhocompleted
6C of TMZ and discontinued treatment to those of patients who continued
TMZ.6C.METHODOLOGY:Weperformedapooledanalysis of4 random-
ized trials (EORTC/NCIC 26981-CE.3; EORTC26071-CENTRIC; EMD-
CORE; RTOG 0525-Intergroup). All patients received the standard of care
(TMZ/RTwith TMZ). All patients who completed TMZ6C and had not pro-
gressedwithin 28dayswere included. Basedon local practice and the discretion
of the investigator TMZ could be continued for up to 12C. Patients were
grouped into those who completed 6C TMZ and those who continued .6C;
progression-free and overall survival were analyzed, adjusted by age, perfor-
mance status, resection extent, and MGMT status. Exploratory analyses with
and without MGMT data imputation were performed at 5% significance.
RESULTS: Independent of evaluated prognostic factors, treatment with .6C
TMZ was significantly associated with improved PFS [HR 0.77 (0.61-0.97),
p¼ 0.03]. This effect was more pronounced in patients with methylated
MGMT [HR 0.64 (0.47-0.88), p, 0.01]. However, OS was not affected by
the number of TMZ cycles, including the MGMT methylated subgroup (p ¼
0.99). Prognostic factors between 6C vs .6C groups were well-balanced,
except MGMT methylation status; methylated status was less frequent in pa-
tients receiving .6C (39% vs 62%). Prognostic factors including age,
MGMTmethylation,extentof resection,andperformancestatushadanexpect-
ed impact on outcomes. CONCLUSION: Increasing the number of cycles of
TMZ beyond 6 months is not shown to increase OS. PFS was improved, more
so in patients withMGMT-methylated tumors.
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